{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:48:59Z","timestamp":1788220139226,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-024-01859-3","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T07:04:37Z","timestamp":1726124677000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Filling the data gap on CGRP mAb therapy in low- to middle-income countries in Southeast Asia: insights from a real-world study in Thailand"],"prefix":"10.1186","volume":"25","author":[{"given":"Prakit","family":"Anukoolwittaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akarin","family":"Hiransuthikul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanakit","family":"Pongpitakmetha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sekh","family":"Thanprasertsuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanakorn","family":"Rattanawong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"issue":"11","key":"1859_CR1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"GBDH Collaborators","year":"2018","unstructured":"Collaborators GBDH (2018) Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the global burden of Disease Study 2016. Lancet Neurol 17(11):954\u2013976","journal-title":"Lancet Neurol"},{"issue":"9","key":"1859_CR2","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/j.1526-4610.1989.hed2909594.x","volume":"29","author":"K Phanthumchinda","year":"1989","unstructured":"Phanthumchinda K, Sithi-Amorn C (1989) Prevalence and clinical features of migraine: a community survey in Bangkok, Thailand. Headache 29(9):594\u2013597","journal-title":"Headache"},{"issue":"1","key":"1859_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38(1):1\u2013211","journal-title":"Cephalalgia"},{"issue":"1","key":"1859_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R et al (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention \u2013\u20092022 update. J Headache Pain 23(1):67","journal-title":"J Headache Pain"},{"issue":"4","key":"1859_CR5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","volume":"64","author":"AC Charles","year":"2024","unstructured":"Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A (2024) Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache 64(4):333\u2013341","journal-title":"Headache"},{"issue":"7","key":"1859_CR6","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/head.14737","volume":"64","author":"YJ Zhao","year":"2024","unstructured":"Zhao YJ, Ong JJY, Sonu SK, Dang J, Ng CC, Herr KJ et al (2024) A real-world prospective observational study of eptinezumab in Asian patients with migraine. Headache 64(7):810\u2013824","journal-title":"Headache"},{"issue":"1","key":"1859_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s10194-023-01611-3","volume":"24","author":"N Vandenbussche","year":"2023","unstructured":"Vandenbussche N, Pisarek K, Paemeleire K (2023) Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review. J Headache Pain 24(1):75","journal-title":"J Headache Pain"},{"issue":"5","key":"1859_CR8","doi-asserted-by":"publisher","first-page":"333102423117764","DOI":"10.1177\/03331024231177649","volume":"43","author":"K Suzuki","year":"2023","unstructured":"Suzuki K, Suzuki S, Shiina T, Tatsumoto M, Fujita H, Haruyama Y et al (2023) Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: a 12-month, single-center, observational real-world study in Japan. Cephalalgia 43(5):3331024231177649","journal-title":"Cephalalgia"},{"issue":"1","key":"1859_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12883-023-03521-y","volume":"24","author":"M Shibata","year":"2024","unstructured":"Shibata M, Fujita K, Hoshino E, Minami K, Koizumi K, Okada S et al (2024) Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers. BMC Neurol 24(1):32","journal-title":"BMC Neurol"},{"issue":"8","key":"1859_CR10","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1177\/03331024221076481","volume":"42","author":"S Kwon","year":"2022","unstructured":"Kwon S, Gil YE, Lee MJ (2022) Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients. Cephalalgia 42(8):705\u2013714","journal-title":"Cephalalgia"},{"key":"1859_CR11","volume-title":"Guidelines for the diagnosis and treatment of migraine headache by the Headache Study Group under the Neurological Society of Thailand (Complete Edition 2022","author":"T Asawavichienjinda","year":"2022","unstructured":"Asawavichienjinda T, Thanprasertsuk S, Anukoolwittaya P (2022) Guidelines for the diagnosis and treatment of migraine headache by the Headache Study Group under the Neurological Society of Thailand (Complete Edition 2022. Thana Press Co., Ltd, Bangkok"},{"issue":"3","key":"1859_CR12","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s13311-022-01230-x","volume":"19","author":"F Cohen","year":"2022","unstructured":"Cohen F, Yuan H, DePoy EMG, Silberstein SD (2022) The arrival of Anti-CGRP monoclonal antibodies in Migraine. Neurotherapeutics 19(3):922\u2013930","journal-title":"Neurotherapeutics"},{"issue":"1","key":"1859_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.31524\/bkkmedj.2018.02.003","volume":"14","author":"K Vongvaivanich","year":"2020","unstructured":"Vongvaivanich K, Yongprawat T, Jindawong N, Chansakul C (2018) Test-Retest Reliability of the Thai Migraine Disability Assessment (Thai-MIDAS) Questionnaire in Thai Migraine Patients. Bangk Med J 14(1):10\u201310","journal-title":"Bangk Med J"},{"issue":"3","key":"1859_CR14","doi-asserted-by":"publisher","first-page":"333102424122860","DOI":"10.1177\/03331024241228605","volume":"44","author":"HC Diener","year":"2024","unstructured":"Diener HC, May A (2024) New migraine drugs: a critical appraisal of the reason why the majority of migraine patients do not receive an adequate medication. Cephalalgia 44(3):3331024241228605","journal-title":"Cephalalgia"},{"issue":"4","key":"1859_CR15","doi-asserted-by":"publisher","first-page":"333102424124565","DOI":"10.1177\/03331024241245658","volume":"44","author":"W Rattanawong","year":"2024","unstructured":"Rattanawong W, Rapoport A, Srikiatkhachorn A (2024) Medication underuse headache. Cephalalgia 44(4):3331024241245658","journal-title":"Cephalalgia"},{"issue":"1","key":"1859_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s10194-023-01556-7","volume":"24","author":"K Ihara","year":"2023","unstructured":"Ihara K, Ohtani S, Watanabe N, Takahashi N, Miyazaki N, Ishizuchi K et al (2023) Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study. J Headache Pain 24(1):23","journal-title":"J Headache Pain"},{"issue":"1","key":"1859_CR17","doi-asserted-by":"publisher","first-page":"14825","DOI":"10.1038\/s41598-023-42110-4","volume":"13","author":"SA Kim","year":"2023","unstructured":"Kim SA, Jang H, Lee MJ (2023) Predictors of galcanezumab response in a real-world study of Korean patients with migraine. Sci Rep 13(1):14825","journal-title":"Sci Rep"},{"issue":"1","key":"1859_CR18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s10194-022-01498-6","volume":"23","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Egeo G, Aurilia C, Altamura C, d\u2019Onofrio F, Finocchi C et al (2022) Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain 23(1):138","journal-title":"J Headache Pain"},{"key":"1859_CR19","unstructured":"Caronna E, Gallardo VJ, Egeo G, Vazquez MM, Castellanos CN, Membrilla JA et al (2024) Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world. J Neurol Neurosurg Psychiatry.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/38777579\/."},{"issue":"6","key":"1859_CR20","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1080\/00325481.2022.2080381","volume":"134","author":"A Krymchantowski","year":"2022","unstructured":"Krymchantowski A, Silva-Neto RP, Jevoux C, Krymchantowski AG (2022) Brazilian descriptive study of 104 consecutive real-world migraine patients treated with monoclonal antibodies. Postgrad Med 134(6):598\u2013602","journal-title":"Postgrad Med"},{"issue":"5","key":"1859_CR21","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40263-021-00818-9","volume":"35","author":"C Sun-Edelstein","year":"2021","unstructured":"Sun-Edelstein C, Rapoport AM, Rattanawong W, Srikiatkhachorn A (2021) The evolution of Medication Overuse Headache: history, pathophysiology and clinical update. CNS Drugs 35(5):545\u2013565","journal-title":"CNS Drugs"},{"key":"1859_CR22","doi-asserted-by":"publisher","first-page":"100094","DOI":"10.1016\/j.ynpai.2022.100094","volume":"12","author":"W Rattanawong","year":"2022","unstructured":"Rattanawong W, Rapoport A, Srikiatkhachorn A (2022) Neurobiology of migraine progression. Neurobiol Pain 12:100094","journal-title":"Neurobiol Pain"},{"issue":"7","key":"1859_CR23","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/head.14154","volume":"61","author":"R Ishii","year":"2021","unstructured":"Ishii R, Schwedt TJ, Dumkrieger G, Lalvani N, Craven A, Goadsby PJ et al (2021) Chronic versus episodic migraine: the 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. Headache 61(7):992\u20131003","journal-title":"Headache"}],"updated-by":[{"DOI":"10.1186\/s10194-025-01962-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000}}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01859-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-024-01859-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01859-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T13:31:53Z","timestamp":1738243913000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-024-01859-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1859"],"URL":"https:\/\/doi.org\/10.1186\/s10194-024-01859-3","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]},"assertion":[{"value":"15 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s10194-025-01962-z","URL":"https:\/\/doi.org\/10.1186\/s10194-025-01962-z","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval was obtained from the ethics committee of Chulalongkorn University (IRB no. 706\/2023). The procedures used in this study adhere to the tenets of the Declaration of Helsinki. The approval of retrieving retrospective data from electronic medical records (EMR) was made and informed consent was waived by IRBREC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}